AbbVie and Johnson & Johnson are two of the largest and most established names in global healthcare, yet they represent very different approaches to growth. AbbVie is a focused biopharmaceutical company whose stock comparison with more diversified peers has drawn renewed attention as its immunology franchise accelerates, while Johnson & Johnson spans pharmaceuticals and medical devices following its consumer-health spin-off. For investors weighing relative performance, market positioning, and risk, this pairing highlights the trade-off between concentrated innovation-driven momentum and diversified, steady-state scale. Both dividend-paying names appeal to long-term and income-oriented investors, but their recent catalysts and sentiment have diverged meaningfully in recent weeks.
ABBV, AbbVie Inc., is a research-based biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics. Its market positioning has strengthened in recent weeks as Skyrizi and Rinvoq together now generate nearly half of revenue, more than offsetting the long-running decline of legacy blockbuster Humira. In its most recent quarter, AbbVie reported roughly 10% year-over-year revenue growth and robust demand for its neuroscience portfolio, while management modestly trimmed full-year adjusted EPS (earnings per share) guidance tied to the acquisition of Apogee Therapeutics. Recent catalysts include FDA (U.S. Food and Drug Administration) approval of a subcutaneous Skyrizi regimen for Crohn's disease and positive late-stage results for lutikizumab. The stock trades near its 52-week high, reflecting strong momentum but also a richer valuation that has prompted some profit-taking.
JNJ, Johnson & Johnson, operates through two segments: Innovative Medicine and MedTech (medical technology). Its diversified model provides stability but also exposes it to separate headwinds. In its most recent quarter, total sales rose about 6% year over year, led by Innovative Medicine growth of roughly 8%, while MedTech growth slowed to the low single digits. Management raised full-year guidance, but adjusted EPS declined year over year, and the company recorded a $5.5 billion pre-tax talc litigation charge. Ongoing competition from Stelara biosimilars remains a drag, partly offset by strength in Darzalex, Tremfya, and newer oncology therapies. Johnson & Johnson shares have posted a strong 12-month advance, though near-term sentiment softened following the latest results.
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, but not all are equally suited to current conditions. The Trending AI Robots page curates only the most relevant strategies for today's market environment, spotlighting bots with standout recent performance and consistency. Each bot carries a distinct trading style, strategy, timeframe, risk profile, and set of tickers, so traders can evaluate options that align with their own approach. This curated selection is updated to reflect shifting conditions, making it a useful starting point for investors comparing automated strategies on stocks like ABBV and JNJ. Explore the page to review the featured bots and their statistics.
The core contrast between these two stocks is concentration versus diversification. AbbVie's growth is driven disproportionately by a handful of immunology products, which creates upside when the pipeline delivers but adds sensitivity to pricing and competition. Johnson & Johnson's broader Innovative Medicine and MedTech mix smooths results but also mutes headline growth. On valuation, JNJ trades at a lower forward earnings multiple than ABBV, which has re-rated higher in recent months on pipeline optimism. From a momentum standpoint, ABBV has trended more consistently toward new highs, while JNJ pulled back after its latest earnings despite raised guidance. Risk factors also differ: AbbVie faces Humira erosion and acquisition-related integration costs, whereas Johnson & Johnson contends with talc litigation, biosimilar pressure, and MedTech softness. Sector exposure is similar on the pharmaceutical side, but JNJ adds device-cycle sensitivity that ABBV lacks.
Based on observable factors such as trend consistency, catalyst flow, and relative positioning, Tickeron's AI would likely lean toward ABBV in the current environment. AbbVie has sustained a steadier upward trend near its 52-week high, supported by a pipeline of approvals and positive clinical data, even as its valuation appears fuller. JNJ offers a lower multiple and a diversified base but has faced near-term sentiment pressure from litigation charges and slowing MedTech growth. This is a probabilistic assessment of relative market positioning rather than a forecast of future returns, and either stock may outperform depending on how upcoming catalysts and macro conditions unfold.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABBV declined for three days, in 126 of 273 cases, the price declined further within the following month. The odds of a continued downward trend are 46%.
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 26 of 69 cases where ABBV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 38%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 19 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 40%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 51 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 226 of 353 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 42 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 165 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 124 of 260 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
ABBV | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 2 | |
SMR RATING 1..100 | 1 | 37 | |
PRICE GROWTH RATING 1..100 | 12 | 11 | |
P/E GROWTH RATING 1..100 | 91 | 7 | |
SEASONALITY SCORE 1..100 | 17 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for JNJ (76). This means that ABBV’s stock grew significantly faster than JNJ’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as JNJ (2). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (37). This means that ABBV’s stock grew somewhat faster than JNJ’s over the last 12 months.
JNJ's Price Growth Rating (11) in the Pharmaceuticals Major industry is in the same range as ABBV (12). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
JNJ's P/E Growth Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (91). This means that JNJ’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | JNJ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 40% | N/A |
| Stochastic ODDS (%) | 2 days ago 38% | 2 days ago 42% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 50% |
| MACD ODDS (%) | 2 days ago 40% | 2 days ago 53% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 47% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 50% |
| Advances ODDS (%) | 7 days ago 61% | 5 days ago 46% |
| Declines ODDS (%) | 15 days ago 46% | 7 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 38% | 2 days ago 44% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 48% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while JNJ’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 3 TA indicator(s) are bullish while JNJ’s TA Score has 6 bullish TA indicator(s).
ABBV (@Pharmaceuticals: Major) experienced а +0.43% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +0.16% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.62%. For the same industry, the average monthly price growth was -0.24%, and the average quarterly price growth was +4.35%.
ABBV is expected to report earnings on Feb 03, 2027.
JNJ is expected to report earnings on Jan 26, 2027.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.16% | ||
| NVS - ABBV | 52% Loosely correlated | -0.19% | ||
| JNJ - ABBV | 51% Loosely correlated | -1.12% | ||
| BMY - ABBV | 50% Loosely correlated | -0.79% | ||
| AMGN - ABBV | 49% Loosely correlated | -0.72% | ||
| GILD - ABBV | 47% Loosely correlated | -0.30% | ||
More | ||||